Mumbai, February 14, 2026 (Saturday) – Fabtech Technologies Limited (NSE: FABTECH | BSE: 544558) has secured an international order valued at USD 7.05 million, equivalent to approximately ₹63.6 crore, for the supply, installation and commissioning of infrastructure for an Oral Solid Dosage facility in West Africa.
The company informed exchanges that the contract has been awarded by an international entity, with the customer’s name withheld due to confidentiality obligations.
Order Details and Execution Timeline
As outlined in the company’s disclosure dated February 14, 2026, the contract involves a comprehensive agreement covering supply, installation and commissioning of infrastructure for an OSD facility.Key Contract Particulars
| Particulars | Details |
|---|---|
| Awarding Entity | A Company in West Africa (name withheld) |
| Nature of Contract | Supply, Installation and Commissioning of Infrastructure |
| Facility Type | Oral Solid Dosage (OSD) |
| Order Classification | International |
| Order Value | USD 7,050,000 (Approx. ₹63.6 crore) |
| Execution Timeline | 23–27 months from receipt of advance |
The execution period is scheduled over 23 to 27 months from the date of receipt of advance payment, indicating a medium-term revenue visibility for the engineering and project execution pipeline.
Governance and Related Party Position
The company clarified that the promoter, promoter group or group companies do not have any interest in the awarding entity. Additionally, the contract does not fall within related party transactions.About Fabtech Technologies Limited
Fabtech Technologies Limited is engaged in providing engineering solutions and infrastructure development services, particularly for pharmaceutical manufacturing facilities. The company is listed on the National Stock Exchange of India and BSE Limited under the symbol FABTECH and scrip code 544558, respectively.The order win enhances the company’s international footprint and adds to its execution pipeline over the next two years.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.